Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).
Hidaka H, Izumi N, Aramaki T, Ikeda M, Inaba Y, Imanaka K, Okusaka T, Kanazawa S, Kaneko S, Kora S, Saito H, Furuse J, Matsui O, Yamashita T, Yokosuka O, Morita S, Arioka H, Kudo M, Arai Y.
Hidaka H, et al. Among authors: aramaki t.
Med Oncol. 2019 May 3;36(6):52. doi: 10.1007/s12032-019-1272-2.
Med Oncol. 2019.
PMID: 31053989